Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoCath/Endocare Deal Aimed At Minimally Invasive Cardiac Surgery Market

This article was originally published in The Gray Sheet

Executive Summary

CryoCath anticipates that its five-year exclusive global supply and market access agreement with Endocare will allow for the development of a cryoablation device that can be used in keyhole surgery.

You may also be interested in...



Endocare Cryocare

Minimally-invasive cryosurgical system gains 510(k) clearance for "keyhole" thoracoscopic cardiac tissue ablation procedures to treat arrhythmias. The clearance opens the door for "a new generation of devices currently under development that treat certain cardiac conditions in a less invasive fashion" under a September 2001 strategic alliance with CryoCath Technologies (1"The Gray Sheet" Oct. 1, 2001, p. 30)...

Endocare Cryocare

Minimally-invasive cryosurgical system gains 510(k) clearance for "keyhole" thoracoscopic cardiac tissue ablation procedures to treat arrhythmias. The clearance opens the door for "a new generation of devices currently under development that treat certain cardiac conditions in a less invasive fashion" under a September 2001 strategic alliance with CryoCath Technologies (1"The Gray Sheet" Oct. 1, 2001, p. 30)...

Endocare Gains Clearance For Benign Breast Tumor Therapy; Malignant Next

Endocare will follow up its FDA 510(k) clearance of the Visica minimally invasive cryoablation system for benign breast tumors with a submission for malignant tumors.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel